# A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

> **NCT07209449** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 75 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Elacestrant

## Key facts

- **NCT ID:** NCT07209449
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-10-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07209449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07209449, "A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT07209449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*